|
|
||||||||
FIELD ACTION REPORT |
The authors are with the San Francisco Department of Public Health, STD Prevention and Control Services, San Francisco, Calif.
Correspondence: Requests for reprints should be sent to Katherine Steiner, MPH, 1360 Mission St, Suite 401, San Francisco, CA 94103 (e-mail: kate.steiner{at}sfdph.org).
| ABSTRACT |
|---|
|
|
|---|
In 1998, treatment completion was low among chlamydia and gonorrhea cases reported to the San Francisco Department of Public Health and assigned for treatment follow-up.
To improve treatment completion among growing numbers of chlamydia and gonorrhea cases, the department implemented field-delivered therapy (FDT), a single-dose, directly observed therapy protocol for uncomplicated chlamydial and gonococcal infections. After the protocol was implemented in March 1999, the proportion of cases completing treatment increased significantly, from 61.8% in 1998 to 81.0% in 2000. The greatest increases in treatment completion were observed for females and individuals younger than 20 years old.
FDT is an effective, feasible, and convenient way to reach and treat individuals who are unlikely to return for chlamydia and gonorrhea treatment.
| INTRODUCTION |
|---|
|
|
|---|
However, a proportion of detected, asymptomatic infections remain untreated either because people cannot be found after their initial screening for treatment follow-up or because some people are not motivated to make a clinical treatment visit for asymptomatic infection. During 1998, 38% (165 of 432) of people assigned for chlamydia and gonorrhea treatment follow-up by the STD program staff of the San Francisco Department of Public Health were not treated. In addition, new noninvasive urine-based nucleic acid amplification tests allowed us to expand screening in nonclinical settings in 1999, further increasing the number of chlamydial and gonococcal infections detected and needing treatment follow-up.
Given the high proportion of untreated cases and increased case detection, innovative approaches to increasing treatment were needed. Field delivery of medication was an integral part of directly observed therapy for tuberculosis6 but no similar protocol was in place for STD treatment. Because single-dose, orally administered treatments were available for chlamydia and gonorrhea and because directly observed therapy had been successful in ensuring treatment for tuberculosis,6 the San Francisco Department of Public Healths STD program implemented a similar protocol in March 1999. We called our program fielddelivered therapy (FDT).
The objective of FDT was to allow STD program field staff, under the medical license of the STD controller, to treat uncomplicated chlamydial and gonococcal infections in persons who were unable, unwilling, or unlikely to come into the municipal STD clinic for treatment. We evaluated the FDT protocol by measuring the number of individuals accepting medication in the field, determining the proportion of individuals treated, and characterizing the population receiving field treatment.
| THE PROTOCOL OF FIELD-DELIVERED THERAPY |
|---|
|
|
|---|
KEY FINDINGS
|
| DISCUSSION AND EVALUATION |
|---|
|
|
|---|
|
FIELD-DELIVERED THERAPY PACK
|
The percentage of cases receiving treatment increased across all age, race, and gender/ sexual orientation categories, with the greatest increases observed for women and persons younger than 20 years (Table 1
). Among men who have sex with men (MSM), treatment completion was very high, above 90% in 1998 and 2000. We believe this is because MSM in San Francisco are more conscientious of their sexual health as a result of the HIV epidemic. Excluding MSM, further stratification by gender showed large increases in the percentage of White women (123.1% increase, P < .001) and Hispanic women (67.9% increase, P = .001) treated. Among non-MSM males, increases were seen for individuals younger than 20 (76% increase, P = .002) and for African Americans (40.8% increase, P = .003).
|
FIELD-DELIVERED THERAPY PROTOCOL
|
There was an increase in the number of staff workers treating follow-up cases during this time; however, since these people also had other duties, the total amount of staff time spent on treatment follow-up remained roughly the same. Thus, it is unlikely that the increase in treatment is entirely explained by these staff changes.
FDT is not only effective in increasing treatment completion, but it is feasible and convenient. As staff were already working in the field to locate patients, FDT was a natural extension of these activities at little additional cost. Although a formal cost analysis has not been done, we expect that FDT is cost saving since it saves clinician time and prevents complications associated with untreated infections. FDT is also convenient for patients, eliminating the need for a return trip to the clinic.
| NEXT STEPS |
|---|
|
|
|---|
FDT is an effective, feasible, and convenient means to ensure treatment completion in these demographic groups. As many health departments already have staff that work in the field, other localities should evaluate FDT as a new tool for STD control.
| Acknowledgments |
|---|
Human Participant Protection
We collected data during routine public health activities of disease control and analyzed data for program evaluation. This activity was therefore designated as public health practice and non-research. In accordance with the Code of Federal Regulations, Title 45, Part 46, The Public Service Act, human subjects review is not required for public health non-research activities.
| Footnotes |
|---|
K. C. Steiner conducted the data analysis and led the writing. C. K. Kent directed the analysis and assisted with writing and editing the manuscript. V. Davila and L. Fischer were responsible for drafting the protocol, training staff, and implementing field-delivered therapy. J. K. Chaw contributed to the data analysis. J. D. Klausner conceived the protocol and supervised its implementation. All authors reviewed drafts of the manuscript.
Accepted for publication December 18, 2002.
| References |
|---|
|
|
|---|
2. Cates W, Wasserheit JN. Genital chalmydial infections: epidemiology and reproductive sequelae. Am J Obstet Gynecol. 1991;164:17711781.[ISI][Medline]
3. Sweet RL. Pelvic Inflammatory disease: etiology, diagnosis, and treatment. Sex Transm Dis. 1981;8(suppl 4): 308315.[Medline]
4. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect. 1999;75:317.[Abstract]
5. Korenromp EL, Sudaryo MK, de Vlas SJ, et al. What proportion of episodes of gonorrhoea and chlamydia becomes symptomatic? Int J STD AIDS. 2002;13:91101.
6. Chaulk CP, Kazandjian VA. Directly observed therapy for treatment completion of pulmonary tuberculosis, consensus statement of the Public Health Tuberculosis Guidelines Panel. JAMA. 1998;279:943948.
This article has been cited by other articles:
![]() |
L M Niccolai, J R Ickovics, K Zeller, T S Kershaw, S Milan, J B Lewis, and K A Ethier Knowledge of sex partner treatment for past bacterial STI and risk of current STI Sex. Transm. Inf., June 1, 2005; 81(3): 271 - 275. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. J. Moss, A. Gallaread, J. Siller, and J. D. Klausner "Street Medicine": Collaborating With a Faith-Based Organization to Screen At-Risk Youths for Sexually Transmitted Diseases Am J Public Health, July 1, 2004; 94(7): 1081 - 1084. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Halterman, P. G. Szilagyi, H. L. Yoos, K. M. Conn, J. M. Kaczorowski, R. J. Holzhauer, S. C. Lauver, T. L. Neely, P. M. Callahan, and K. M. McConnochie Benefits of a School-Based Asthma Treatment Program in the Absence of Secondhand Smoke Exposure: Results of a Randomized Clinical Trial Arch Pediatr Adolesc Med, May 1, 2004; 158(5): 460 - 467. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |